A Phase 2, Adaptive, Randomized, Open-label, Assessor-blinded Active-controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Standard of Care in Patients Suffering From ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as ...

Greece on Monday prosecuted a pair of protected witnesses for alleged perjury in a long-running bribery probe involving the Swiss pharmaceutical firm Novartis, a justice source said. The man and woman ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...

TIN-816 is under clinical development by Novartis and currently in Phase II for Sepsis. According to GlobalData, Phase II drugs for Sepsis have a 50% phase transition success rate (PTSR) indication ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took another zig on Thursday with a federal appellate court blocking the ...

Novartis (NVS) has filed a lawsuit accusing the Biden administration of unlawfully preventing the company from changing payment terms to some hospitals that participate in the 340B Drug Discount ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto. Novartis on Thursday secured a last-minute win against MSN ...